Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
— 2015-05-14Volume 356, Issue 9232, 2 September 2000, Pages 802-807
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial.
This research paper show the positive effect of immunotherapy for cancer patients.
Background
Postsurgical recurrence of hepatocellular carcinoma (HCC=liver cancer) is frequent and fatal. Adoptive immunotherapy is active against HCC. We assessed whether postoperative immunotherapy could lower the frequency of recurrence.
Methods
Between 1992 and 1995, we did a randomised trial in which 150 patients who had undergone curative resection for HCC were assigned adoptive immunotherapy (n=76) or no adjuvant treatment (n=74). Autologous lymphocytes activated vitro with recombinant interleukin-2 and antibody to CD3 were infused five times during the first 6 months. Primary endpoints were time to first recurrence and recurrence-free survival and analyses were by intention to treat.
Effect on prevention recurrence through Immunotherapy
Adoptive immunotherapy is a safe, feasible treatment that can lower recurrence and improve recurrence-free outcomes after surgery for HCC. Adoptive immunotherapy is no longer thought to be useful because clinical success has been confined to melanoma, renal cancer, and lymphoma.
– The recurrence rate after liver cancer surgery is 75~80% generally.
– whereas the recurrence rate after both the surgery and immunotherapy.
– Control group – 74, Immunotherapy group – 76 of 150 patients after hepatectomy, randomized trial
– After 2weeks, 3weeks, 4weeks, 3months, 6months after operation. – total 5 times immunotherapy.
[Adoptive immunotherapy decreased the frequency of recurrence by 18% compared with controls and first recurrence was delayed for 14 months.]
Conclusion
–Â Immunotherapy Group
Recurrence free – 41%
AVG. of first recurrence – about 33 months
–Â Control Group
Recurrence – 23%
AVG. of first recurrence – about 19 month
Keyword : Adoptive immunotherapy , Cancer spread, Overall recurrence, Early recurrence, Local recurrence, Extensive recurrence, Distant metastasis, Multicentric tumour
Source :
www.ncbi.nlm.nih.gov/pubmed/11022927
http://www.sciencedirect.com/science/article/pii/S0140673600026544
www.ncbi.nlm.nih.gov/pubmed/11022927
http://www.sciencedirect.com/science/article/pii/S0140673600026544
Related Articles
-
-
-
YOUR GUIDE TO SHEEP PLACENTA
2021-11-18 -
Coronavirus: Stem Cell therapy
2020-03-03 -
Cancer Immunology Novel Prize 2018
2018-10-10 -
-
-
Stress and Immune System
2016-02-13 -
When immune systems couple up
2016-03-09 -
Aging, alopecia, and stem cells
2016-02-13 -
-
Stem Cell Therapy will help hearing loss.
2015-10-19 -
Every cell, off the peg
2015-10-19 -
-
Cell and number
2015-08-25
-
Bio Trends
The cells began to divide.
— 2015-04-27The cells began to divide. How many human cells die daily? For adults it’s about 50-70 billion per day. Surprising?…
-
Health Care & Ageless
How can we get adult stem cells?
— 2015-04-27Stem Cell Collection, Stem Cell Collecting, Stem Cell Harvesting Stem cells could be collected from our body’s various tissues as…
-
Statistics Research
Average life span and Healthy span
— 2015-04-28Average life span and Healthy span in Korea, 2014. The gap between average life span and healthy span is…
-
Slow Aging Research
How to retain youth
— 2015-05-05Doctors say how to retain youth. 1. Anti-wrinkle : Taking enough water is more important than using a anti-wrinkle…
English 
Korean 
Japanese
Leave a reply
You must be logged in to post a comment.